Tumor Ablation Market Analysis & Forecast: 2026-2033
The global tumor ablation market was valued at USD 1,755.7 Mn in 2026 and is forecast to reach a value of USD 3,741.1 Mn by 2033 at a CAGR of 11.5% between 2026 and 2033.
The tumor ablation market is primarily driven by the rising global incidence of cancer, which increases demand for effective therapies; a growing preference for minimally invasive procedures due to faster recovery and fewer complications; and technological advancements in ablation devices and image-guided systems that improve precision and broaden clinical applications. These factors collectively expand adoption and market growth worldwide.
|
Current Event |
Description and Its Impact |
|
AI Integration and Advanced Imaging Technologies |
|
|
Regulatory Harmonization and Approval Acceleration |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of technology, the radiofrequency ablation segment is expected to lead the market with 36% share in 2026, due to it is safe, cost-effective and widely used in clinics. Physicians prefer RFA because it minimal invasive and works well on many types of cancer. Its established infrastructure and familiarity among healthcare providers ensure it remains the leading technology, even as newer modalities gain traction.
For instance, in April 2025, The British Thyroid Foundation stated that the RABBIT trial will recruit for patients with benign thyroid nodules to take part. This study's goal is to evaluate if radiofrequency ablation is a minimally invasive alternative to surgery. It will access safety, effectiveness, and patient outcomes, which could lead to more treatment options for people with thyroid problems that are not cancerous.
In terms of treatment, the percutaneous ablation segment is expected to hold 58% share of the market in 2026, because it is less invasive, has shorter recovery times, and fewer problems. Patients benefit from less pain and a quicker discharge, and doctors like the precision of it. The growing demand for outpatient procedures and improvements in technology make it even more popular than surgical and laparoscopic options.
For instance, in September 2025, the FDA has granted Techsomed's BioTraceIO360 platform 510(k) clearance for kidney ablation, which adds to its previous liver tumor indication. This AI-driven, image-guided therapy makes minimally invasive care more consistent, bettering planning, guidance, and verification. It improves the accuracy of predicting ablation zones, which moves interventional oncology precision forward, caused by data from multicenter trials.
In terms of application, the liver cancer segment is projected to account for 31% share in 2026, driven by hepatocellular carcinoma prevalence around the world and there is strong clinical evidence that ablation therapies work. Tumor ablation offers efficient local management, particularly for patients ineligible for surgical intervention. The increasing number of liver cancer cases around the world means that this part will still be the most important in 2026.
For instance, in January 2026, Jersey Shore University Medical Center will start offering histotripsy for liver tumors from February 2026. It will be the only hospital in Monmouth and Ocean counties to do so. The HistoSonics Edison system uses focused ultrasound to turn tumors into liquid without hurting nearby tissue.
To learn more about this report, Download Free Sample
North America is expected to dominate the tumor ablation market with 42% share in 2026, owing to the advanced healthcare infrastructure, the widespread use of minimally invasive procedures, and the good reimbursement policies. The rise in cancer cases, along with new technologies in imaging guidance and ablation devices, makes it easier for patients to accept and for doctors to use them in their practices.
For instance, in January 2026, IceCure Medical proposed guidelines from the American Society of Breast Surgeons that include cryoablation as a treatment option for low-risk breast cancer. The award shows that cryoablation could be a good option for patients minimally invasive alternative to surgery. It provides effective care with shorter recovery times and is becoming more widely used in clinics.
Asia Pacific is expected to exhibit the fastest growth, due to rising cancer prevalence, healthcare infrastructure is improving quickly, and growing awareness about minimally invasive treatments. increasing investment in oncology care, and wider access to advanced medical technologies, resulting in accelerating adoption, making the region the fastest-growing market in the world.
For instance, in November 2025, Profound Medical stated it had signed a strategic distribution deal with Getz Healthcare to bring its TULSA-PRO® system to Australia and New Zealand. The AI-powered, MRI-guided technology uses robot-controlled ultrasound to treat the prostate without making any reductions. This partnership makes it easier for more people to get precise prostate care, which improves patient outcomes and speeds up the use of new treatments in the region.
The Tumor Ablation Market is expected to be highly demanding in the U.S. in 2025 due to cancer rates are going up, healthcare infrastructure is getting better, and minimally invasive procedures has strong adoption rate. The market is developing into more integrated into clinical settings because of good reimbursement policies, new technologies in ablation devices, and more patients wanting to have their treatments done in an outpatient setting.
For instance, in December 2025, Pulse Biosciences and MD Anderson have started a study to evaluate a new type of ablation technology for thyroid cancer. The study will look into the safety and efficacy of Nano-Pulse Stimulation is as a therapy that targets cells without using heat. The goal of this partnership is to give thyroid cancer patients more options for minimally invasive treatments and better results.
Japan's Tumor Ablation Market is in high demand due to greater numbers of individuals are getting cancer, the population is getting older, and people are more likely to choose minimally invasive procedures. Technological progress, government support for cancer research, and more money spent on health care all help to drive adoption, making ablation a key option for precision oncology care.
For instance, in October 2025, Gunze Medical, which is part of Gunze Limited, has signed an exclusive deal with HistoSonics to bring its noninvasive ultrasound platform and its own histotripsy-based sonic beam therapy to Japan. The goal of the partnership is to bring cutting-edge treatment technology to all parts of the country, improving accuracy, efficiency, and patient care.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,755.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.5% | 2033 Value Projection: | USD 3,741.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic, Johnson & Johnson Services Inc., Boston Scientific Corporation, IceCure Medical, EDAP TMS, Theraclion, H.S. Hospital Service SPA and AngioDyna mics. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The global cancer cases are continuously rising, with liver, lung, kidney, and bone cancers are some of the most common types. There is a strong need for effective, minimally invasive treatments because the number of cases is rising so quickly. Tumor ablation is a targeted method that cuts down on hospital stays and makes patients better. As the number of people with cancer rises around the world, the Tumor Ablation Market growth is propelled by increasing adoption these procedures. This makes them an important part of modern cancer care plans.
Patients and healthcare systems are increasingly choosing minimally invasive treatments over traditional surgery. Radiofrequency, microwave, cryoablation, and HIFU are all types of ablations that help people heal faster, have fewer complications, and cost less overall. This preference is changing how treatments are given, especially for patients who are poor candidates for surgery. As hospitals and clinics add ablation technologies to their standard cancer care protocols, the tumor ablation market demand is directly increasing, as more people want to use these advanced techniques.
For instance, in June 2025, Hygea Medtech announced ISMIO 2025, a global conference in which experts from different countries showcased the latest ways to remove tumors. The event focuses on new developments in minimally invasive oncology, encouraging teamwork, sharing of knowledge, and progress in clinical settings. The goal is to speed up the use of new ablation technologies and make patients better around the world.
Tumor ablation is no longer limited to liver and lung cancers; it is being investigated for breast, prostate, and bone tumors. This diversification greatly increases the number of patients and makes it easier for people in many oncology specialties to use it. Ablation technologies are likely to become an important part of modern cancer care because they offer minimally invasive options for a wider range of cancers. The Tumor Ablation Market forecast predicts strong growth as clinical uses grow and more doctors and patients accept them.
For instance, in October 2025, Researchers at Sichuan University developed a mid-infrared laser method that targets pancreatic ductal adenocarcinoma (PDAC) by taking advantage of its collagen-rich structure. The 6.1-micron wavelength only destroys tumor tissue and leaves healthy pancreas tissue alone. This minimally invasive method could lower the risk of complications during surgery, keep organs working well, and lead to more precise cancer treatments for tumors with collagen.
Definition: Tumor ablation is a minimally invasive surgical process to cure solid malignancy. Special probes are utilized to heat or freeze malignancy without the general operation. Computed Tomography, Ultrasound or Magnetic Resonance Imaging is utilized to guide and position the needle probe into the cancer. This needs only a tiny hole, generally below 3 mm through which the probe is presented.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
